Research letter
Omalizumab in severe asthma: Evaluation of the clinical impact after its withdrawal
M. D. de Sousaa,, , C. Ferreirab, A. Arrobasb
a Centro Hospitalar Tondela Viseu, Viseu, Portugal
b Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Dear Editor,

Omalizumab is a monoclonal anti-IgE antibody approved for the treatment of uncontrolled severe persistent allergic asthma.1 Although several studies have shown its benefits,2–4 the optimal duration of the therapy and the effect after its withdrawal remains unknown.

We performed a study to assess the clinical effect of Omalizumab discontinuation, in patients with severe asthma. A current re-evaluation was conducted through questionnaires of asthma control, respiratory function tests and assessment on exacerbations.

Ten patients were included, all women, with a mean age of 49.5 years. All patients responded to Omalizumab therapy according to the GETE scale (Global Effectiveness Treatment Evaluation). The average time of treatment was 43.4±21.7 months (min. 9, max. 73). Omalizumab was stopped in 7 patients for clinical stability, and in the other 3 for complications (1 stroke, 1 breast cancer and another for severe anaemia). The median time from discontinuation of therapy was 28±25.3 months (min. 5, max. 76).

In our re-evaluation, the mean Control Allergic Rhinitis and Asthma test (CARAT) decreased from 21.6±6.6 to 19.9±7.8 and mean fractional exhaled nitric oxide (FeNO) value increased from 28.3±11.1 to 29.03±29.9ppb. Forced expiratory volume in 1s (FEV1) increased from 60.5±20.7% to 60.8±18.4%. The number of exacerbations within the last 12 months increased from 0.6±1.1 to 2.1±2.4 (Fig. 1).

Figure 1.

Number of exacerbations/last 12 months at the end of treatment versus re-evaluation.

Individual analysis showed a decrease in asthma control in 3 cases (30%), an increase in exacerbations was also observed in 4 patients (40%), and none of them had had exacerbations over the past 12 months at the end of treatment. The mean time to the first exacerbation was 6±5.1 months, and three patients had an exacerbation in the first 6 months. Two of these patients had been the most severe patients at the beginning based on ACT scores; they were under treatment for variable lengths of time (25/42/52 months).

During the 7 months follow up period, Omalizumab has already been reintroduced in one patient.

In the literature, there are only a few evaluations of patients following suspension of Omalizumab, with different study designs and inconsistent results.

The biggest report is from Nopp et al.5 who published a 1 long-term study (n=18) with a 3-year period of observation after Omalizumab suspension, where one third of the patients lost their asthma control. Molimard et al.6 performed a retrospective observational study in severe asthmatic patients (n=61) after discontinuation of Omalizumab therapy and loss of control was observed in 34 patients (55.7%); Omalizumab was reintroduced in 20 out of these 34 patients, but 20% of them became non-responders despite previous sensitivity.

Looking at our patients and at the studies described, it seems reasonable to maintain Omalizumab (beyond the standard period of 5 years7)/to reintroduce it in patients with frequent exacerbations who achieved control after Omalizumab treatment.

Besides the possibility of losing asthma control, there is a risk of secondary resistance to Omalizumab.6

Therefore, decisions on cessation of Omalizumab treatment should always be undertaken individually after weighing all the benefits and risks.

Conflicts of interest

The authors have no conflicts of interest to declare.

K.F. Chung,S.E. Wenzel,J.L. Brozek,A. Bush,M. Castro,P.J. Sterk
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Eur Respir J, 43 (2014), pp. 343-373
I. Abraham,A. Alhossan,C.S. Lee,H. Kutbi,K. MacDonald
‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review
Allergy, 71 (2016), pp. 593-610
S. Alfarroba,W. Videira,C. Galvao-Lucas,F. Carvalho,C. Barbara
Clinical experience with omalizumab in a Portuguese severe asthma unit
Rev Port Pneumol, 20 (2014), pp. 78-83
A.S. Sousa,A.M. Pereira,J.A. Fonseca,L.F. Azevedo,C. Abreu,A. Arrobas
Asthma control and exacerbations in patients with severe asthma treated with omalizumab in Portugal
Rev Port Pneumol, (2015),
A. Nopp,S.G. Johansson,J. Adedoyin,J. Ankerst,M. Palmqvist,H. Oman
After 6 years with Xolair; a 3-year withdrawal follow-up
M. Molimard,L. Mala,I. Bourdeix,V. Le Gros
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
Respir Med, 108 (2014), pp. 571-576
I. Kuprys-Lipinska,P. Kuna
Loss of asthma control after cessation of omalizumab treatment: real life data
Postepy Dermatol Alergol, 31 (2014), pp. 1-5
Corresponding author.
Copyright © 2017. Sociedade Portuguesa de Pneumologia


  • Impact Factor: 1.357(2015)
  • 5-years Impact Factor: 0,841
  • SCImago Journal Rank (SJR):0,29
  • Source Normalized Impact per Paper (SNIP):0,685